These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23048078)

  • 1. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
    Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
    Adams S; Kozhaya L; Martiniuk F; Meng TC; Chiriboga L; Liebes L; Hochman T; Shuman N; Axelrod D; Speyer J; Novik Y; Tiersten A; Goldberg JD; Formenti SC; Bhardwaj N; Unutmaz D; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6748-57. PubMed ID: 22767669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
    Ito H; Ando T; Arioka Y; Saito K; Seishima M
    Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer treatment with imiquimod: applying an old lotion to a new disease.
    Kohrt H
    Clin Cancer Res; 2012 Dec; 18(24):6571-3. PubMed ID: 23172886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
    Lu H; Wagner WM; Gad E; Yang Y; Duan H; Amon LM; Van Denend N; Larson ER; Chang A; Tufvesson H; Disis ML
    J Immunol; 2010 May; 184(9):5360-7. PubMed ID: 20308630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
    Salazar LG; Lu H; Reichow JL; Childs JS; Coveler AL; Higgins DM; Waisman J; Allison KH; Dang Y; Disis ML
    JAMA Oncol; 2017 Jul; 3(7):969-973. PubMed ID: 28114604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
    Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
    Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
    Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
    J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
    Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
    Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
    Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
    Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
    Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
    J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
    Xiong Z; Ohlfest JR
    J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy.
    Ondo AL; Mings SM; Pestak RM; Shanler SD
    J Am Acad Dermatol; 2006 Dec; 55(6):1092-4. PubMed ID: 17097406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
    Fishelevich R; Zhao Y; Tuchinda P; Liu H; Nakazono A; Tammaro A; Meng TC; Lee J; Gaspari AA
    J Immunol; 2011 Aug; 187(4):1664-73. PubMed ID: 21765012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
    Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
    Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation by imiquimod in patients with high-risk primary melanoma.
    Narayan R; Nguyen H; Bentow JJ; Moy L; Lee DK; Greger S; Haskell J; Vanchinathan V; Chang PL; Tsui S; Konishi T; Comin-Anduix B; Dauphine C; Vargas HI; Economou JS; Ribas A; Bruhn KW; Craft N
    J Invest Dermatol; 2012 Jan; 132(1):163-9. PubMed ID: 21850019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
    Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
    J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.